# Drug of interest
My drug of interest is pyrimethamine.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. CYP2C19 (z: 3.81)
2. ABCB1 (z: 2.77)
3. ABCG2 (z: 2.2)
4. G6PD (z: 1.95)
5. SLC22A1 (z: 1.6)
6. ABCC2 (z: 1.38)
7. CYP2D6 (z: 1.18)
8. SLCO1B1 (z: 1.09)
9. IKBKG (z: 1.05)
10. CYP2C9 (z: 1.0)
11. CYP2D7 (z: 0.95)
12. NR1I2 (z: 0.9)
13. SLC22A3 (z: 0.87)
14. UGT2B7 (z: 0.82)
15. CYP2S1 (z: 0.77)
16. ABCB4 (z: 0.75)
17. CYP3A4 (z: 0.73)
18. SLC22A2 (z: 0.73)
19. SLCO1A2 (z: 0.69)
20. ABCC4 (z: 0.69)
21. UGT1A4 (z: 0.68)
22. CYP2B6 (z: 0.65)
23. CYP3A5 (z: 0.62)
24. UGT1A1 (z: 0.6)
25. UGT2B15 (z: 0.55)
26. CYP2C18 (z: 0.54)
27. HNF4A (z: 0.52)
28. CYP2A7 (z: 0.52)
29. SLCO1B3 (z: 0.51)
30. ABCG8 (z: 0.51)
31. HLA-C (z: 0.5)
32. ABCC3 (z: 0.5)
33. HLA-A (z: 0.49)
34. CYP2C8 (z: 0.48)
35. RUNDC3B (z: 0.47)
36. SLC22A7 (z: 0.47)
37. ABCC11 (z: 0.47)
38. ABCC1 (z: 0.47)
39. MTHFR (z: 0.46)
40. UGT1A6 (z: 0.46)
41. UGT2A1 (z: 0.46)
42. CYP2A13 (z: 0.46)
43. UGT1A7 (z: 0.46)
44. SLC19A1 (z: 0.45)
45. UGT1A10 (z: 0.45)
46. HLA-B (z: 0.44)
47. UGT1A8 (z: 0.43)
48. UGT1A9 (z: 0.42)
49. CYP2F1 (z: 0.42)
50. ABCC5 (z: 0.42)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**pyrimethamine**: Pyrimethamine's pharmacogenetic interactions involve the enzyme CYP2C8, which affects its metabolism, and the transporters SLC47A1 and SLC47A2, which impact its transport; polymorphisms in these genes can alter the drug's efficacy and toxicity, necessitating possible dosing adjustments. Additionally, gene variants in G6PD and IKBKG could influence treatment responses and risk profiles in certain parasitic infections through their roles in cellular processes and immune responses.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**SLC22A1**: The gene SLC22A1, encoding for the organic cation transporter 1 (OCT1), significantly influences the absorption and distribution of various drugs, such as metformin, tramadol, lamotrigine, ondansetron, rasagiline, and imatinib, by affecting their hepatic uptake. Genetic variations in SLC22A1 can lead to different efficacy and safety profiles for these drugs, necessitating potential dosage adjustments in the management of conditions like diabetes, pain, epilepsy, nausea, Parkinson’s disease, and chronic myeloid leukemia.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**IKBKG**: The interactions between the IKBKG gene and antimalarial drugs such as pyrimethamine, artesunate, sulfadoxine, and primaquine are largely pharmacodynamic, affecting the NF-kappaB signaling pathway and consequently impacting the immune response needed to combat malaria. Mutations in the IKBKG gene can modify the immune system's response, thus potentially influencing the efficacy of these drugs in individuals with such genetic variations.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**SLC22A3**: The gene SLC22A3, or OCT3, influences the pharmacokinetics of drugs like metformin and potentially antidepressants like citalopram by affecting their cellular uptake and distribution. Variants in SLC22A3 can lead to altered drug efficiency and side effect profiles by impacting the transporter efficiency and thus the intracellular concentrations of these medications.

**UGT2B7**: UGT2B7 is crucial in the metabolism and clearance of various drugs, including opioids like morphine and buprenorphine, antiretrovirals such as zidovudine, antiepileptics like valproic acid, cardiovascular drugs, and NSAIDs among others, influencing their efficacy, side effects, and toxicity. Genetic variability in UGT2B7 can significantly impact the pharmacokinetics and therapeutic outcomes of these drugs, which may require personalized dosing to optimize benefits and minimize adverse reactions.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**SLC22A2**: SLC22A2, functioning as the organic cation transporter 2 (OCT2), plays a key role in the renal elimination of various drugs, including metformin, acyclovir, ganciclovir, oxaliplatin, cimetidine, and l-tryptophan, with genetic variations affecting their pharmacokinetics. Reduced activity of SLC22A2 can limit the elimination of drugs like metformin, potentially increasing its efficacy but also raising the risk of toxicity, while other drugs might experience altered efficacy and safety due to changes in exposure levels caused by interactions and competition at the transporter level.

**SLCO1A2**: The gene SLCO1A2 significantly affects the pharmacokinetics of drugs like rocuronium, imatinib, and methotrexate by mediating their hepatic uptake, which alters their effectiveness, safety, and systemic clearance. Rocuronium's performance in anesthesia, imatinib's therapeutic outcomes in cancer treatment, and methotrexate's response in treating malignancies and autoimmune disorders are all influenced by variations in SLCO1A2 activity, impacting their hepatic clearance and overall drug dynamics.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**UGT1A4**: UGT1A4 catalyzes the glucuronidation of drugs such as lamotrigine, atorvastatin, valproic acid, methotrexate, testosterone, tamoxifen, anastrozole, olanzapine, and n-desmethylclozapine, affecting their solubility, detoxification, and excretion. Genetic variations in UGT1A4 can significantly alter the metabolism of these drugs, including lamotrigine and hormonal treatments like testosterone and tamoxifen, impacting their therapeutic effectiveness and risk of toxicity, which is crucial for managing conditions ranging from epilepsy and cholesterol to hormone-sensitive disorders and psychiatric conditions.

**CYP2B6**: CYP2B6 plays a pivotal role in the metabolism of several drugs, including efavirenz, nevirapine, methadone, bupropion, cyclophosphamide, and ifosfamide, where genetic polymorphisms can significantly influence drug efficacy and safety by altering pharmacokinetic profiles. Genetic variations in CYP2B6 affect the enzyme activity, leading to differences in drug plasma concentrations, therapeutic effects, and potential adverse reactions in individuals, underscoring its importance in personalized medicine.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**UGT1A1**: UGT1A1 plays a critical role in drug metabolism primarily through glucuronidation, affecting both pharmacokinetics and pharmacodynamics. For example, the gene’s variations, like UGT1A1*28, reduce the clearance of drugs such as irinotecan's active metabolite SN-38, leading to severe side effects and requiring dosage adjustments. Similarly, UGT1A1 influences the metabolism of HIV drugs like atazanavir and indinavir, impacting their effectiveness and concentration in the body. This gene also affects the metabolism of other medications such as atorvastatin, impacting treatments across various therapeutic areas like cancer and lipid management.

**UGT2B15**: UGT2B15 is an enzyme involved in the metabolism of numerous drugs including lorazepam, oxazepam, acetaminophen, and lamotrigine, primarily through the process of glucuronidation which aids in their excretion. Genetic variants in UGT2B15 can alter enzyme activity, impacting the effectiveness and toxicity of these drugs by affecting their plasma concentrations and systemic availability.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**HNF4A**: HNF4A, a transcription factor, influences the pharmacokinetics of drugs like rosuvastatin, efavirenz, and lamotrigine, where variations in HNF4A can alter drug metabolism, affecting their effectiveness and safety. Furthermore, HNF4A may affect the pharmacodynamics of drugs such as metformin, warfarin, docetaxel, and irinotecan by altering gene expression that impacts metabolic enzymes and pathways, thereby modifying drug efficacy and patient response.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**SLCO1B3**: SLCO1B3, which encodes the organic anion transporting polypeptide 1B3 (OATP1B3), plays a crucial role in the hepatic uptake and metabolism of several drugs including docetaxel, mycophenolate mofetil, telmisartan, and voriconazole, affecting their plasma levels, therapeutic effects, and toxicity. Variants in this gene can modify the transport efficiency of these drugs, influencing their absorption, distribution, elimination, and overall pharmacokinetics, thereby necessitating tailored dosing in personalized medicine to enhance efficacy and reduce adverse effects.

**ABCG8**: The ABCG8 gene influences the effectiveness of ezetimibe, a drug that reduces cholesterol by targeting a sterol transporter formed by ABCG8 and ABCG5, which limits cholesterol absorption in the intestines. Variations in ABCG8 can alter this transporter's activity, impacting ezetimibe’s efficacy, while the effects of these variations on atorvastatin and simvastatin (drugs that inhibit cholesterol synthesis via a different mechanism) are less direct and may operate through altered cholesterol metabolism and feedback mechanisms.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**ABCC3**: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of drugs such as methotrexate and morphine by affecting their transport. Variants in ABCC3 can lead to altered excretion of methotrexate, which affects its effectiveness and side effects, and can modify the transport of morphine and its metabolites, impacting their systemic and neurological effects. Other chemotherapy drugs like doxorubicin and vincristine may also interact with ABCC3, potentially influencing drug efficacy and resistance through effects on drug efflux.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**SLC22A7**: Genetic variations in the SLC22A7 gene, which encodes for the Organic Anion Transporter 3 (OAT3), significantly affect the renal excretion and therefore the clearance, efficacy, and toxicity of various drugs such as cefotaxime, oseltamivir, doxorubicin, daunorubicin, and capecitabine. These interactions might influence not just the pharmacokinetics but also the therapeutic and toxic effects of these drugs due to the role of OAT3 in altering their availability at cellular or tissue levels.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**ABCC1**: ABCC1, a critical gene encoding for an efflux transporter, significantly affects the pharmacokinetics and pharmacodynamics of various drugs by impacting their absorption, distribution, and elimination. Notably, it modulates the clearance of anticancer drugs like SN-38 and doxorubicin from cells, contributing to drug resistance and variability in therapeutic efficacy and toxicity, which is particularly relevant in optimizing cancer chemotherapy. Other drugs such as vincristine, methotrexate, and ritonavir, among others, also demonstrate pharmacogenetic interactions with ABCC1, affecting treatment outcomes especially in oncology.

**MTHFR**: MTHFR genetic variants impact the efficacy and toxicity of drugs like folic acid, methotrexate, and capecitabine by affecting folate metabolism and homocysteine levels. Folic acid supplementation can address elevated homocysteine levels, while MTHFR mutations can alter methotrexate processing and enhance or reduce capecitabine activation, influencing drug dosages and resulting pharmacodynamic outcomes. Additionally, drugs such as phenytoin and carbamazepine exhibit non-metabolic interactions with MTHFR variants through effects on folate homeostasis, which may affect drug effectiveness and side-effect profiles.

**UGT1A6**: UGT1A6 is a key enzyme involved in the metabolism of several drugs through glucuronidation, influencing their solubility and excretion. Specific genetic variants of UGT1A6 can alter the metabolism and effectiveness of drugs like atorvastatin and acetaminophen, potentially affecting their efficacy and toxicity. Additionally, it processes drugs such as valproic acid, methotrexate, aspirin, and other NSAIDs, where genetic differences can impact drug levels, exposure, and side effect profiles, playing a significant role in pharmacokinetics and potentially pharmacodynamics.

**UGT2A1**: UGT2A1, a gene in the UDP-glucuronosyltransferase family involved in detoxification, might influence the pharmacokinetics of drugs like imatinib, which is metabolized through glucuronidation by related enzymes. Although there is no direct evidence linking UGT2A1 with imatinib, variations in UGT2A1 could potentially affect imatinib's metabolism, efficacy, and toxicity, even if the exact relationship remains speculative and unconfirmed.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**UGT1A7**: UGT1A7, an enzyme involved in drug metabolism, significantly influences the effectiveness and safety of drugs such as atorvastatin, axitinib, valproic acid, and methotrexate by affecting their clearance and plasma levels. Variations in UGT1A7 activity can lead to diverse therapeutic outcomes and adverse effects, like muscle and liver toxicity, by altering the metabolism of these drugs, indicating the need for careful consideration of UGT1A7 variability in drug prescription and therapy management.

**SLC19A1**: The gene SLC19A1, which encodes a folate transporter protein, significantly influences the pharmacokinetics of antifolate medications such as methotrexate by affecting its cellular uptake, thus altering drug efficacy and toxicity. Variants in SLC19A1 can lead to differences in methotrexate transport into cells, impacting the necessity for personalized dosing strategies, and potentially affecting other similar chemotherapy drugs, although the extent of interaction may vary.

**UGT1A10**: UGT1A10 is involved in the metabolism of drugs like atorvastatin, axitinib, valproic acid, methotrexate, and irinotecan through glucuronidation, impacting their bioavailability, elimination, and therapeutic levels. This enzyme's activity variances can alter drug efficacy and side effect profiles, making the personalization of dosages based on genetic makeup imperative for optimizing therapeutic outcomes and minimizing adverse effects.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**UGT1A8**: UGT1A8 plays a crucial role in the metabolism of drugs such as atorvastatin, axitinib, valproic acid, methotrexate, and raloxifene by catalyzing their glucuronidation, leading to the formation of water-soluble glucuronide conjugates that facilitate drug excretion. Variants in the UGT1A8 gene can modify the activity of the enzyme, thereby affecting the concentration, efficacy, and toxicity of these drugs, with notable effects on drugs like irinotecan, where altered metabolism significantly impacts its toxicity profile.

**UGT1A9**: UGT1A9 plays a key role in the glucuronidation and metabolism of various drugs, including NSAIDs like diclofenac, antiretrovirals, and chemotherapy agents like irinotecan. Genetic variations in UGT1A9 can significantly influence the pharmacokinetics and pharmacodynamics of these drugs, affecting their efficacy and the severity of side effects such as neutropenia, particularly evident in treatments involving mycophenolic acid and irinotecan.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.
